近日,在2025年第30届欧洲血液学协会(EHA)年会上,复星国际(00656.HK)旗下复星医药自主研发的MEK1/2抑制剂芦沃美替尼(FCN-159)治疗复发/难治性朗格汉斯细胞组织细胞增生症(LCH)儿童患者的关键研究成果重磅发布,为其科学应用再添新证。日前,芦沃美替尼片完成首批发货,已在上海、北京、广东、山东、江苏、湖南等多个省市医院开出首批处方,正式投入临床使用。芦沃美替尼是一种高选择性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.